Swiss study to track new kidney drug in 50 patients
NCT ID NCT07555301
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will follow 50 adults with IgA nephropathy who are taking sparsentan. Researchers want to see how the drug affects protein in the urine (albuminuria), a key sign of kidney damage. The study is observational, meaning it just watches what happens in real-world use, without giving any treatment or placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY (IGAN) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Long-Term Safety of Atacicept for IgA Nephropath NCT06674577
- LO-PAIgN: Loin Pain in IgA Nephropathy Study NCT07649538
- Nefecon for IgA Nephropathy Relapse Prevention – NCT07604311
- RESIGAN: Observational Study on IgA Nephropathy NCT06926244
- HSK39297 for IgA Nephropathy Long-Term Safety (NCT07616700)
- Brain-Gut-Kidney Axis in IgA Nephropathy MRI Stu NCT07617402
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stadtspital Zurich
Zurich, Canton of Zurich, 8000, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••